Quality of life with tandem ureteral stents compared to percutaneous nephrostomy for malignant ureteral obstruction.

Lower urinary tract symptoms Percutaneous nephrostomy Quality of life Stents Ureteral obstruction

Journal

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957

Informations de publication

Date de publication:
Nov 2022
Historique:
received: 05 04 2022
accepted: 26 08 2022
pubmed: 4 9 2022
medline: 8 11 2022
entrez: 3 9 2022
Statut: ppublish

Résumé

Malignant ureteral obstruction (MUO) is treated with kidney decompression by a percutaneous nephrostomy (PCN) or internal ureteral stents. The objective of this study was to compare quality of life (QoL) with a PCN compared to tandem ureteral stents (TUS) in cases of MUO. We reviewed the medical records of patients with MUO who were treated by PCN/TUS in our institution between June 2019 and May 2020. Patients were asked to fill out a QoL questionnaire, a tube-symptoms questionnaire, report a general health scale, and asked for a drain preference if they had experience with both drains. Scores of both groups were compared and predictors of all QoL and tube-symptoms measures were searched using multivariate analysis. Seventy-four patients with a PCN and 30 with TUS were included in the study. No statistically significant difference was found in all QoL and tube-symptoms measurements between the two drains. Type of drain was not found to be a predictor of QoL or tube-related symptoms. Eighty-four percent of patients (11/13) who have experience with both types of drains preferred TUS. TUS and PCN for relief of MUO have a negative and similar effect on various areas of QoL and urinary symptoms. Most patients who had experience with both types of drains preferred TUS over PCN. In this patient population with a grim prognosis, this negative effect must be communicated to patients, and calculated against the potential benefits of drainage.

Identifiants

pubmed: 36056940
doi: 10.1007/s00520-022-07354-2
pii: 10.1007/s00520-022-07354-2
doi:

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

9541-9548

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Ganatra AM, Loughlin KR (2005) The management of malignant ureteral obstruction treated with ureteral stents. J Urol 174:2125–2128
doi: 10.1097/01.ju.0000181807.56114.b7 pubmed: 16280741
Kouba E, Wallen EM, Pruthi RS (2008) Management of ureteral obstruction due to advanced malignancy: optimizing therapeutic and palliative outcomes. J Urol 180:444–450
doi: 10.1016/j.juro.2008.04.008 pubmed: 18550089
Elsamra SE, Leavitt DA, Motato HA et al (2015) Stenting for malignant ureteral obstruction: tandem, metal or metal-mesh stents. Int J Urol 22:629–636
doi: 10.1111/iju.12795 pubmed: 25950837
Liu KL, Lee BC, Ye JD et al (2019) Comparison of single and tandem ureteral stenting for malignant ureteral obstruction: a prospective study of 104 patients. Eur Radiol 29:628–635
doi: 10.1007/s00330-018-5560-6 pubmed: 29974220
Haifler M, Kleinmann N, Weiss D (2021) Tandem ureteral stents drainage lowers renal pelvis pressure in malignant ureteral obstruction: experimental and computational models. J Biomech 117:110237
doi: 10.1016/j.jbiomech.2021.110237 pubmed: 33486265
Haifler M, Shvero A, Zilberman D et al (2020) Tandem ureteral stents for malignant ureteral obstruction. J Endourol 34:222–226
doi: 10.1089/end.2019.0685 pubmed: 31724450
Alma E, Ercil H, Vuruskan E et al (2020) Long-term follow-up results and complications in cancer patients with persistent nephrostomy due to malignant ureteral obstruction. Support Care Cancer 28:5581–5588
doi: 10.1007/s00520-020-05662-z pubmed: 32757161
Irani J, Siquier J, Pirès C, Lefebvre O, Doré B, Aubert J (1999) Symptom characteristics and the development of tolerance with time in patients with indwelling double-pigtail ureteric stents. BJU Int 84:276–279
doi: 10.1046/j.1464-410x.1999.00154.x pubmed: 10468721
Misra S, Coker C, Richenberg J (2013) Percutaneous nephrostomy for ureteric obstruction due to advanced pelvic malignancy: have we got the balance right? Int Urol Nephrol 45:627–632
doi: 10.1007/s11255-013-0458-3 pubmed: 23666587
Monsky WL, Molloy C, Jin B et al (2013) Quality-of-life assessment after palliative interventions to manage malignant ureteral obstruction. Cardiovasc Intervent Radiol 36:1355–1363
doi: 10.1007/s00270-013-0571-9 pubmed: 23404519 pmcid: 4601638
Joshi HB, Stainthorpe A, Keeley FX, MacDonagh R, Timoney AG (2001) Indwelling ureteral stents: evaluation of quality of life to aid outcome analysis. J Endourol 15:151–154
doi: 10.1089/089277901750134421 pubmed: 11325084
Herdman M, Gudex C, Lloyd A et al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20:1727–1736
doi: 10.1007/s11136-011-9903-x pubmed: 21479777 pmcid: 3220807
Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley FX, Timoney AG (2003) Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol 169:1060–1064
doi: 10.1097/01.ju.0000049198.53424.1d pubmed: 12576846
Shoshany O, Erlich T, Golan S et al (2019) Ureteric stent versus percutaneous nephrostomy for acute ureteral obstruction - clinical outcome and quality of life: a bi-center prospective study. BMC Urol 19:79–85
doi: 10.1186/s12894-019-0510-4 pubmed: 31455309 pmcid: 6712738
Joshi HB, Okeke A, Newns N, Keeley FX, Timoney AG (2002) Characterization of urinary symptoms in patients with ureteral stents. Urology 59:511–516
doi: 10.1016/S0090-4295(01)01644-2 pubmed: 11927301
Elbatanouny AM, Ragheb AM, Abdelbary AM et al (2020) Percutaneous nephrostomy versus JJ ureteric stent as the initial drainage method in kidney stone patients presenting with acute kidney injury: a prospective randomized study. Int J Urol 27:916–921
doi: 10.1111/iju.14331 pubmed: 32851713
Xu RH, Wong ELY, Jin J, Huang H, Dong D (2021) Health-related quality of life measured using EQ-5D in patients with lymphomas. Support Care Cancer 29:2549–2560
doi: 10.1007/s00520-020-05774-6 pubmed: 32949297
Savin Z, Herzberg H, Ben-David R et al (2021) Long-term follow-up of yearly replaced double internal stents for extrinsic malignant ureteral obstruction. J Endourol 35:71–76
doi: 10.1089/end.2020.0469 pubmed: 32668988
Kinjo M, Nakamura Y, Taguchi S et al (2021) Sex differences in prevalence and patient behavior regarding lower urinary tract symptoms among Japanese medical checkup examinees. Urology 151:24–30
doi: 10.1016/j.urology.2020.05.065 pubmed: 32540299

Auteurs

Asaf Shvero (A)

Department of Urology, Sheba Medical Center, Ramat-Gan, Israel. asaf.shvero@sheba.health.gov.il.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. asaf.shvero@sheba.health.gov.il.

Miki Haifler (M)

Department of Urology, Sheba Medical Center, Ramat-Gan, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Husny Mahmud (H)

Department of Urology, Sheba Medical Center, Ramat-Gan, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Zohar Dotan (Z)

Department of Urology, Sheba Medical Center, Ramat-Gan, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Harry Winkler (H)

Department of Urology, Sheba Medical Center, Ramat-Gan, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Nir Kleinmann (N)

Department of Urology, Sheba Medical Center, Ramat-Gan, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH